No Data
Absci Started by Guggenheim at Buy on Pioneer Status in AI Drug Design
Absci Initiated at Buy by Guggenheim
Guggenheim Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $10
Is Absci (NASDAQ:ABSI) Using Debt In A Risky Way?
Black horse rises! AI startup receives support from OpenAI, only 6 months since its establishment.
①Chai Discovery, a biotechnology startup company that has been established for nearly half a year, raised nearly $300 million in the latest round of financing at a valuation of $1.5 billion; ②According to Chai, the company's developed AI basic model can predict the structure of biochemical molecules and reprogram their interactions, a process that is crucial for the development of new drugs.
Truist Financial Maintains Absci Corp(ABSI.US) With Buy Rating
Truist Financial analyst Srikripa Devarakonda maintains $Absci Corp(ABSI.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 57.6% and a total average return of 6.1%